Mon, November 15, 2021

Corinne Jenkins Downgraded (BTAI) to Strong Sell and Decreased Target to $24 on, Nov 15th, 2021

Corinne Jenkins of Goldman Sachs, Downgraded "BioXcel Therapeutics, Inc." (BTAI) to Strong Sell and Decreased Target from $55 to $24 on, Nov 15th, 2021.

Corinne, nor any peers, have made any analyst calls on BTAI in the last 4 months.

Warning: Undefined array key "user_peer_history" in /tmp/a6c06072cf4de09d3b84c924bfa9ab126ebc2b66_0.file.analysis.tpl.php on line 30